杭州安旭生物科技股份有限公司2025年半年度报告摘要

Core Viewpoint - The company, Hangzhou Anxu Biotechnology Co., Ltd., has released its 2025 semi-annual report, which includes details on its financial status, operational results, and future development plans [1][7]. Group 1: Company Overview - The company is identified by the stock code 688075 and is referred to as Anxu Biotechnology [1]. - The report emphasizes the importance of reading the full semi-annual report for a comprehensive understanding of the company's performance and future plans [1]. Group 2: Financial Data - The total amount of funds raised through the public offering was RMB 1,200.30 million, with a net amount of RMB 1,055.85 million after deducting various fees [12]. - As of June 30, 2025, the balance of raised funds was RMB 27.59 million [13]. Group 3: Fund Management - The company has established a management system for the raised funds, ensuring that they are stored in designated special accounts and used according to regulations [14]. - The company has signed tripartite supervision agreements with banks to ensure proper management of the raised funds [15][16]. Group 4: Fund Usage - The company has completed several projects, reallocating surplus funds to new projects, including the "Technical R&D Headquarters Construction Project" with a planned investment of RMB 292.45 million [32][34]. - The company has not used idle raised funds to temporarily supplement working capital as of the reporting period [20]. Group 5: Compliance and Reporting - The company has complied with all relevant regulations regarding the management and use of raised funds, ensuring timely and accurate disclosures [35].